RGNCY-0104 (Roxyl-ZV-5J dual CDK4/VEGFR2 inhibitor)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

Roxyl-ZV-5J is a potent dual inhibitor of CDK4 and VEGFR2 (IC50 of 46nM for each).  Roxyl-ZV-5J significantly induced breast and cervical cancer cell cycle arrest and cell apoptosis.  In HUVEC cells, Roxyl-ZV-5J also inhibited the the proliferation, tube formation and VEGFR2 downstream signalling pathways.  The oral administration of Roxyl-ZV-5J resulted insignificant tumor regression and anti-angiogenesis in the SiHa xenograft mouse model without apparent toxicity.  Roxyl-ZV-5J also exhibited a good pharmacokinetic profile.

Systematic Name:  N-(4-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)phenyl)-N-(p-tolyl)cyclopropane-1,1-dicarboxamide



Formula:  C33H31F2N7O2 

Mol Wt:  595.65

PMID:  31382120

Tags: CDK4, Cancer, Apoptosis, small molecule, angiogenesis, RGNCY-0104, Rxyl-ZV-5J, VEGFR2, HUVEC